Gilead to present Phase 3 Livdelzi data in primary biliary cholangitis at Liver Meeting 2026
GILD•Gilead will present Livdelzi and Hepcludex research at The Liver Meeting in Denver, November 5-9, 2026. The presentations include Phase 3 IDEAL results and analyses of long-term efficacy, safety and symptoms.
1. Planned presentations
Gilead Sciences will present new Livdelzi and Hepcludex data at The Liver Meeting, November 5-9, 2026, in Denver. Phase 3 IDEAL results will examine Livdelzi’s effect on a liver disease marker in adults with primary biliary cholangitis. Other Livdelzi analyses report sustained efficacy and safety through five years and clinically meaningful fatigue improvement.
2. Hepcludex research
Hepcludex research will assess sustained treatment response in chronic hepatitis delta; another analysis suggests improvement in liver-related hypertension for some patients.
